Clinical trials: malaria
Malaria
Longitudinal Antimalarial Combinations in Uganda
The purpose of this study is to compare different ways of treating uncomplicated malaria in a group of Ugandan children. The study will be divided into 2 parts.
- Trial name
- NCT00123552
- Testing
- Amodiaquine+Artesunate, Amodiaquine+Sulfadoxine/Pyrimethamine, Artemether+Lumefantrine
- Where
- Uganda
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Falciparum
MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
A single-centre, open-label, study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection.
- Trial name
- NCT02281344
- Testing
- MMV390048 20mg
- Where
- Australia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
P. Falciparum
Pregnant Women for Malaria Surveillance
Close monitoring of malaria in pregnancy can help to quickly identify changes in malaria burden and related adverse outcomes, especially in areas embarking in malaria elimination activities.
- Trial name
- MiPMon (NCT04412005)
- Testing
- No intervention
- Volunteers
- 16,958 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Malaria
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops.
- Trial name
- DSMOZ-2 (NCT02573857)
- Testing
- DSM265, OZ439
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Severe Anemia
Post-discharge Malaria Chemoprevention(PMC) Study
This study evaluates the efficacy and safety of 3 months of malaria chemoprevention post-discharge using dihydroartemisinin piperaquine (DHA-P) in children under 5 years of age admitted with severe anemia.
- Trial name
- PMC (NCT02671175)
- Testing
- dihydroartemisinin-piperaquine
- Where
- 9 sites in Kenya, Uganda
- Volunteers
- 1,049 people
- Sponsor
- Liverpool School of Tropical Medicine
Malaria
Experimental Falciparum Transmission to Anopheles
This is a single-centre, open-label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the infectivity of sexual life cycle stages of the malaria parasite (gametocytes) to mosquito vectors.
- Trial name
- EFITA (NCT02431637)
- Testing
- Administration of the malaria inoculum, Piperaquine Phosphate 480 mg
- Where
- Australia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
This is a single-centre, controlled, open label study using P. falciparum-induced blood stage malaria (IBSM) infection to assess the effectiveness of OZ439 as a gametocytocidal agent, as well as its treatment effects on…
- Trial name
- OZGAM (NCT02431650)
- Testing
- OZ439, Primaquine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Lymphoma, Non-Hodgkin, Malaria
Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Burkitt lymphoma (BL) is an aggressive monoclonal B-cell malignancy that is rare (sporadic) worldwide, but is 100-fold more common (endemic) in equatorial Africa, particularly among children.
- Conditions
- Lymphoma, Non-Hodgkin, Malaria, Herpesvirus 4, Human
- Trial name
- NCT01196520
- Where
- 6 sites in Tanzania, Uganda
- Volunteers
- 4,893 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Plasmodium Falciparum
A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)
A comparison of Malaria events (symptoms and signs of malaria) experienced by subjects infected with PfSPZ Challenge (NF54) vs. PfSPZ Challenge (7G8).
- Trial name
- ECG-CHMI (NCT04203186)
- Testing
- atovaquone-proguanil
- Volunteers
- healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults
This is a study designed to assess the safety, tolerability, immunogenicity, and protective efficacy of 2 heterologous prime-boost vaccine regimens in healthy, malaria naïve adults.
- Trial name
- NCT03341754
- Testing
- D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Plasmodium Falciparum Malaria
SJ733 Induced Blood Stage Malaria Challenge Study
This is a single-centre, open-label, study using induced blood stage malaria (IBSM) infection to characterize the activity of (+)-SJ000557733 or SJ733 for short, against early Plasmodium falciparum blood stage infection.
- Trial name
- SJ733IBSMCS (NCT02867059)
- Testing
- (+)-SJ000557733
- Where
- 2 sites in Australia
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)
This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 4 sites of the two oral ACTS…
- Trial name
- MEFI_III (NCT04370977)
- Testing
- Coartem™ (Artemether-lumefantrine combination), Winthrop™ (Amodiaquine-artesunate combination)
- Where
- 6 sites in Mozambique
- Volunteers
- 630 people
- Sponsor
- Centro de Investigacao em Saude de Manhica
Vivax Malaria
Methylene Blue Against Vivax Malaria in Ethiopia
Feasibility of methylene blue-based combination therapy in the radical treatment of adult patients with Plasmodium vivax malaria in Ethiopia: a randomised controlled pilot trial Study rationale: Elimination has become the goal of…
- Trial name
- BlueAL (NCT02696928)
- Testing
- Artemeter-Lumefantrine and MB (combination therapy), Artemeter-Lumefantrine (combination therapy), Artemeter-Lumefantrine and Primaquine (combination therapy)
- Sponsor
- Heidelberg University
Malaria, Falciparum
Methylene Blue Against Falciparum Malaria in Burkina Faso
Safety of artesunate-amodiaquine combined with methylene blue or primaquine for falciparum malaria treatment in African children: A randomised controlled trial Elimination has become the goal of malaria programmes in an…
- Trial name
- BlueACTn (NCT02851108)
- Testing
- Methylene Blue, Primaquine
- Where
- Burkina Faso
- Volunteers
- 100 people
- Sponsor
- Heidelberg University
Malaria
Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)
The aim of the study is to determine the tolerability and safety of ATV-PG + AQ, ATV-PG + AQ placebo, ATV-PG placebo + AQ, and ATV-PG placebo + AQ placebo administered once daily for 3 days to healthy adult male and female…
- Trial name
- NCT04002687
- Testing
- ATV-PG 1000-400 mg + AQ 612 mg
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
This is a pilot, double-blind, randomized, parallel-group, placebo-control, exploratory study to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride (5-ALA HCl) and sodium ferrous citrate (SFC) added on…
- Trial name
- NCT04020653
- Testing
- 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD, Sodium ferrous citrate (SFC) 472 mg QD, Artemisinin-based combination (ACT)
- Sponsor
- Neopharma Japan Co., Ltd.
Febrile Illness, Malaria
Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda
Malaria remains a disease that causes much death and sickness, especially in sub-Saharan Africa. An accurate, simple, and inexpensive method of diagnosing malaria is urgently needed.
- Trial name
- NCT00327964
- Where
- Uganda
- Volunteers
- 600 people
- Sponsor
- University of California, San Francisco
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)
In the current randomized trial, the investigators will test the ability of two experimental approaches to malaria infection management to reduce malaria transmission potential.
- Trial name
- NCT03705624
- Testing
- Enhanced Community Case Management (CCM), Monthly Screening and Treatment (MSAT)
- Where
- Burkina Faso
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis
This is an open label, Phase 2 study with controlled human malaria infection (CHMI). Twenty three subjects will be enrolled into 2 groups (15 subjects in the Chloroquine-Azithromycin [CQ/AZ] Intervention Group, and 8 subjects in…
- Trial name
- NCT03278808
- Testing
- Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®)
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Sickle Cell Anemia, Sickle Cell Disease
Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas
The Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM) study is the first placebo-controlled randomized clinical trial of hydroxyurea treatment in a malaria endemic region.
- Conditions
- Sickle Cell Anemia, Sickle Cell Disease, Malaria
- Trial name
- NOHARM-MTD (NCT03128515)
- Testing
- Hydroxyurea
- Where
- Uganda
- Volunteers
- 187 people
- Sponsor
- Indiana University